MP Group- Natural Language Processing: An AI tool to cash-in the ‘big-text’ in life sciences

2020 saw several milestones for the use of Artificial Intelligence (AI) in pharma, including the entry of the first AI-designed molecule in clinical trials. While digital pathology and chemistry/small molecule-oriented AI applications have already found their way into mainstream news, we would like to share with you an outlook on Natural language processing (NLP) - An AI tool to cash-in the ‘big-text’ in life sciences. Pharma has seen an explosion in terms of data. PubMed has more than 30 million citations, clinicaltrialgov has…

Continue Reading

MP Outlook – 2021 and Beyond

At the threshold of this New Year, we are pleased to share the ‘MP Outlook – 2021 and Beyond’ (link to the presentation) where we present our analyses on some of the high-impact areas potentially reshaping BioPharma industry, especially from the learnings due to the pandemic. Some of the key highlights of the presentation are –   BioPharma can no longer afford to spend a decade and a billion dollar in getting a drug to the market. Integration of AI-based platform…

Continue Reading

MP Group – AI toolkit for early-stage drug discovery

Early this year, we shared an outlook giving an overview of the role of Artificial Intelligence in Drug Discovery. Through our conversations with several global pharma and biotechs, we realized that, while the enthusiasm around the potential of AI is high, a shadow of skepticism looms over. A common theme in our dialogs was on explaining the advantages of AI-based interventions over the traditional methods and what to expect out of AI-based platforms. To help build a deeper perspective on AI…

Continue Reading

Next Generation CROs – Differentiated technologies today that will pay-off tomorrow

Historically, CROs have grown by building the scales for the services that pharma cos and biotechs wanted to outsource due to a number of reasons, from reducing the overheads, to cost-effective operations, to downsizing the headcount for effective management, etc. As a result, operational efficiency, large scales and past experiences have been the key value propositions, with relatively lesser focus on differentiated offerings, of course with a few exceptions. However, with BioPharma now riding on a wave of innovative technologies,…

Continue Reading

Biopharma Insight Article: The AI Productivity Game in Pharma

The pharmaceutical business is one of the riskiest industries to venture into. Drug discovery is an artisanal process where a carefully designed drug takes about 10 years and approximately 2.5 billion dollars to be approved and launched into the market. The complexity of biological systems places the odds at a ridiculous failure rate of 90%. In recent years, the declining efficiency of the R&D efforts has put the pharma industry on its toes.  In the past decade, Artificial Intelligence (AI)…

Continue Reading

MP Group – Outlook of Protein Formulation Technologies – Opportunities for IV to subQ Conversion

Currently,~80% of biologics are administered intravenously due to high doses and challenges associated with high concentration protein formulation development – viscosity, stability including aggregation and volume. As a result, patients are tethered to IV infusion set-up for hours, few times a month often in a clinic or hospital, adding significant cost. Subcutaneous delivery enhances patient compliance and convenience, while significantly reducing the cost associated with hospitalization. Only a handful of technologies have attempted to address the protein formulation challenge, that…

Continue Reading

BioSpectrum Article – Time for Asian pharma to up their AI game!

The excitement around Artificial Intelligence’s (AI) potential to transform the drug discovery process has been building up in the biopharma industry. AI-drug discovery starts-ups have boomed in the last decade and billions of dollars have already been poured on the promise of an efficient and agile drug discovery process. AI has influenced all sectors of the drug discovery value chain. Technologies have come up to analyze numerous medical images, to aggregate information from millions of publications for rapid analytics, to…

Continue Reading

MP Group – Overview of Biobetters: IV to SC formulation conversion for patient compliance, healthcare savings, and market differentiation

The key highlights of the presentation are: Biobetters are an improved version of a biologic and provide better efficacy, safety and patient compliance while reducing the overall burden on healthcarePotential opportunity for Biosimilars company for marketplace differentiation and evasion of patent dance, and for Innovators to extend product lifecycle and delay biosimilars threatIntravenous (IV) to subcutaneous (SC) conversion is one of the most prudent strategies to address the unmet need of patient compliance while reducing the overall healthcare costsThe current…

Continue Reading

Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward

LONG-LASTING VEGF BLOCKERS, COMPOUNDS WITH VEGF- INDEPENDENT MECHANISM AND, TOPICAL AND ORAL TREATMENT OPTIONS, BRING THE QUEST FOR THE “IDEAL RETINAL DRUG” A STEP NEARER Multifactorial nature of DME led a definite role of steroids in the current treatment paradigm; development of new route of administration of steroids to enhance clinical efficacy with better safety underway The late stage pipeline comprises of long-lasting VEGF blockers and compounds with VEGF-independent mechanisms such asTie-2/Angiopoietin pathway modulators and integrin inhibitorsNon-invasive therapies, prophylactic alternatives…

Continue Reading

BioSpectrum Article – Face-lifting biopharma industry image

Covid-19 pandemic gives an opportunity for the BioPharma industry to transform its image. Can the initiatives and learnings from Covid-19 be applied to other critical therapy areas?  Can the time and cost of development be significantly reduced such that the pharma companies can launch the products at affordable prices to ensure that every patient gets access to the medicines? Emerging markets are gaining more importance than ever, led by China, considering the scales of volumes they offer. With time and…

Continue Reading
Close Menu